ReviewFrontiers in pharmacology2026
Research progress of small molecule protein kinase inhibitors (SMKIs) in the treatment of colorectal cancer: mechanism, application, and future prospects.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is among the most common malignancies worldwide, and advanced or metastatic disease remains difficult to treat because of tumor heterogeneity, adaptive resistance, pathway redundancy, drug-related toxicity, and limited predictive biomarkers. Small-molecule kinase inhibitors (SMKIs) provide therapeutic opportunities for selected molecular subgroups by targeting key signaling pathways, but their clinical application is still constrained by complex resistance mechanisms, off-target toxicity, and insufficient biomarker-guided stratification. This narrative review summarizes recent progress in SMKIs for CRC, including molecular targets, clinical evidence, resistance mechanisms, combination strategies, and translational directions. Emerging technologies, including multi-omics profiling, artificial intelligence-assisted drug discovery, patient-derived models, liquid biopsy, molecular imaging, multidrug delivery systems, and adaptive trial designs, can be integrated into a translational "discover-validate-monitor-adapt" workflow and may help address some current limitations in targeted drug development for CRC. Future development of SMKI-based therapy in CRC will require biomarker-guided patient selection, rational combination strategies, dynamic monitoring of resistance, and prospective validation using clinically meaningful endpoints.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.